Gastric cancer: Adding glycosylation to the equation

Trends in Molecular Medicine

Volumn 19, Issue 11, 2013, Pages 664-676

  Pinho, Salomé S ^a   Carvalho, Sandra ^a   Marcos Pinto, Ricardo ^a,b   Magalhães, Ana ^a   Oliveira, Carla ^a,c   Gu, Jianguo ^d   Dinis Ribeiro, Mário ^c,e   Carneiro, Fátima ^a,c,f   Seruca, Raquel ^a,c   Reis, Celso A ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b Centro Hospitalar Universitario do Porto   (Portugal)

^c University of Porto   (Portugal)

^d TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^e PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Biomarkers; Cancer; E cadherin; Gastric cancer; Glycosylation; Integrins

Indexed keywords

BETA CATENIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CADHERIN; INTEGRIN; MUCIN 5AC; UVOMORULIN;

ACTIN FILAMENT; BACTERIAL GROWTH; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL ADHESION; CELL INTERACTION; CELL JUNCTION; CELL MIGRATION; EARLY DIAGNOSIS; ENDOCYTOSIS; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC POLYMORPHISM; GLYCOSYLATION; HELICOBACTER PYLORI; HETEROZYGOSITY LOSS; HOST SUSCEPTIBILITY; HUMAN; INTRACELLULAR SIGNALING; MECHANOTRANSDUCTION; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SIALYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; STOMACH GLAND; STOMACH MUCOSA; STOMACH MUCUS; TIGHT JUNCTION;

HELICOBACTER PYLORI;

BIOMARKERS; CANCER; E-CADHERIN; GASTRIC CANCER; GLYCOSYLATION; INTEGRINS;

ANIMALS; GASTRIC MUCOSA; GLYCOSYLATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTEINS; STOMACH NEOPLASMS;

EID: 84886951831     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.07.003     Document Type: Review

References (142)

1. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
3. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10231-10233.
4. Varki A., et al. Essentials of Glycobiology. Glycosylation Changes in Cancer 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, ch 44. 2nd edn.
5. Anderson W.F., et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010, 303:1723-1728.
6. Milne A.N., et al. Nature meets nurture: molecular genetics of gastric cancer. Hum. Genet. 2009, 126:615-628.
7. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 1965, 64:31-49.
8. Vauhkonen M., et al. Pathology and molecular biology of gastric cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:651-674.
9. Figueiredo C., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. 2002, 94:1680-1687.
10. Machado J.C., et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003, 125:364-371.
11. Azevedo M., et al. Infection by Helicobacter pylori expressing the BabA adhesin is influenced by the secretor phenotype. J. Pathol. 2008, 215:308-316.
12. Linden S.K., et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog. 2009, 5:e1000617.
13. Rossez Y., et al. Almost all human gastric mucin O-glycans harbor blood group A, B or H antigens and are potential binding sites for Helicobacter pylori. Glycobiology 2012, 22:1193-1206.
14. Joossens J.V., et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int. J. Epidemiol. 1996, 25:494-504.
15. Marcos-Pinto R., et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment. Pharmacol. Ther. 2012, 35:1451-1459.
16. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52:6735-6740.
17. Dinis-Ribeiro M., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012, 44:74-94.
18. Dinis-Ribeiro M., et al. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J. Gastroenterol. Hepatol. 2007, 22:1594-1604.
19. Worthley D.L., et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012, 61:774-779.
20. Carneiro F., et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J. Pathol. 2004, 203:681-687.
21. Oliveira C., et al. Genetics, pathology, and clinics of familial gastric cancer. Int. J. Surg. Pathol. 2006, 14:21-33.
22. Paredes J., et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim. Biophys. Acta 2012, 1826:297-311.
23. Corso G., et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J. Clin. Oncol. 2013, 31:868-875.
24. Guilford P., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
25. Diaz De Liano A., et al. Impact of surgical procedure for gastric cancer on quality of life. Br. J. Surg. 2003, 90:91-94.
26. Ferlay J., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
27. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
28. Reis C.A., et al. Immunohistochemical study of the expression of MUC6 mucin and co-expression of other secreted mucins (MUC5AC and MUC2) in human gastric carcinomas. J. Histochem. Cytochem. 2000, 48:377-388.
29. Reis C.A., et al. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int. J. Cancer 1998, 79:402-410.
30. Teixeira A., et al. Expression of mucins (MUC1, MUC2, MUC5AC, and MUC6) and type 1 Lewis antigens in cases with and without Helicobacter pylori colonization in metaplastic glands of the human stomach. J. Pathol. 2002, 197:37-43.
31. Lopez-Ferrer A., et al. Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium. Gut 2000, 47:349-356.
32. Mollicone R., et al. Immunohistologic pattern of type 1 (Lea, Leb) and type 2 (X, Y, H) blood group-related antigens in the human pyloric and duodenal mucosae. Lab. Invest. 1985, 53:219-227.
33. Oriol R., et al. Genetic regulation of the expression of ABH and Lewis antigens in tissues. APMIS Suppl. 1992, 27:28-38.
34. Magalhaes A., et al. Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology 2009, 19:1525-1536.
35. Boren T., et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993, 262:1892-1895.
36. Ilver D., et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998, 279:373-377.
37. Aspholm-Hurtig M., et al. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 2004, 305:519-522.
38. Benktander J., et al. Redefinition of the carbohydrate binding specificity of Helicobacter pylori BabA adhesin. J. Biol. Chem. 2012, 287:31712-31724.
39. Gerhard M., et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:12778-12783.
40. Kawakubo M., et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004, 305:1003-1006.
41. Karasawa F., et al. Essential role of gastric gland mucin in preventing gastric cancer in mice. J. Clin. Invest. 2012, 122:923-934.
42. Marcos N.T., et al. Helicobacter pylori induces β3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J. Clin. Invest. 2008, 118:2325-2336.
43. Mahdavi J., et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002, 297:573-578.
44. Reis C.A., et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res. 1999, 59:1003-1007.
45. Conze T., et al. MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas. Glycobiology 2010, 20:199-206.
46. Ferreira B., et al. Terminal α1,4-linked N-acetylglucosamine in Helicobacter pylori-associated intestinal metaplasia of the human stomach and gastric carcinoma cell lines. J. Histochem. Cytochem. 2006, 54:585-591.
47. Gomes C., et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J. Proteome Res. 2013, 12:1454-1466.
48. Feigin M.E., Muthuswamy S.K. Polarity proteins regulate mammalian cell-cell junctions and cancer pathogenesis. Curr. Opin. Cell Biol. 2009, 21:694-700.
49. Nishimura T., Takeichi M. Remodeling of the adherens junctions during morphogenesis. Curr. Top. Dev. Biol. 2009, 89:33-54.
50. Royer C., Lu X. Epithelial cell polarity: a major gatekeeper against cancer?. Cell Death Differ. 2011, 18:1470-1477.
51. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251:1451-1455.
52. Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol. 2005, 6:622-634.
53. Riethmacher D., et al. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:855-859.
54. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
55. Hirohashi S., Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003, 94:575-581.
56. Joo Y.E., et al. Expression of e-cadherin and catenins in early gastric cancer. J. Clin. Gastroenterol. 2002, 35:35-42.
57. Ohene-Abuakwa Y., et al. Expression of the E-cadherin/catenin (α-, β-, and γ-) complex correlates with the macroscopic appearance of early gastric cancer. J. Pathol. 2000, 192:433-439.
58. Oliveira C., et al. Hereditary gastric cancer. Best Pract. Res. Clin. Gastroenterol. 2009, 23:147-157.
59. Ramesh S., et al. Reduction in membranous expression of β-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br. J. Cancer 1999, 81:1392-1397.
60. van Roy F., Berx G. The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 2008, 65:3756-3788.
61. Liwosz A., et al. N-glycosylation affects the molecular organization and stability of E-cadherin junctions. J. Biol. Chem. 2006, 281:23138-23149.
62. Zhou F., et al. Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD. Glycoconj. J. 2008, 25:727-740.
63. Nanes B.A., et al. p120-catenin binding masks an endocytic signal conserved in classical cadherins. J. Cell Biol. 2012, 199:365-380.
64. Pinho S.S., et al. E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim. Biophys. Acta 2013, 1830:2690-2700.
65. Schwartz M.A., DeSimone D.W. Cell adhesion receptors in mechanotransduction. Curr. Opin. Cell Biol. 2008, 20:551-556.
66. Smutny M., Yap A.S. Neighborly relations: cadherins and mechanotransduction. J. Cell Biol. 2010, 189:1075-1077.
67. Figueiredo J., et al. ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS ONE 2011, 6:e23188.
68. Le T.L., et al. Recycling of E-cadherin: a potential mechanism for regulating cadherin dynamics. J. Cell Biol. 1999, 146:219-232.
69. Zhu W., et al. Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO J. 2001, 20:5999-6007.
70. Geng F., et al. Multiple post-translational modifications regulate E-cadherin transport during apoptosis. J. Cell Sci. 2012, 125:2615-2625.
71. Zhao H., et al. N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:140-148.
72. Guo H.B., et al. Regulation of homotypic cell-cell adhesion by branched N-glycosylation of N-cadherin extracellular EC2 and EC3 domains. J. Biol. Chem. 2009, 284:34986-34997.
73. Pinho S.S., et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell. Mol. Life Sci. 2011, 68:1011-1020.
74. Nita-Lazar M., et al. Hypoglycosylated E-cadherin promotes the assembly of tight junctions through the recruitment of PP2A to adherens junctions. Exp. Cell Res. 2010, 316:1871-1884.
75. Vagin O., et al. Inverse correlation between the extent of N-glycan branching and intercellular adhesion in epithelia. Contribution of the Na,K-ATPase β1 subunit. J. Biol. Chem. 2008, 283:2192-2202.
76. Jamal B.T., et al. N-glycosylation status of E-cadherin controls cytoskeletal dynamics through the organization of distinct β-catenin- and γ-catenin-containing AJs. Cell Health Cytoskelet. 2009, 2009:67-80.
77. Pinho S.S., et al. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem. Biophys. Res. Commun. 2009, 379:1091-1096.
78. Pinho S.S., et al. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum. Mol. Genet. 2009, 18:2599-2608.
79. Gu J., et al. A mutual regulation between cell-cell adhesion and N-glycosylation: implication of the bisecting GlcNAc for biological functions. J. Proteome Res. 2009, 8:431-435.
80. Yoshimura M., et al. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 1996, 271:13811-13815.
81. Kitada T., et al. The addition of bisecting N-acetylglucosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of beta-catenin. J. Biol. Chem. 2001, 276:475-480.
82. Pinho S.S., et al. Loss and recovery of Mgat3 and GnT-III mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PLoS ONE 2012, 7:e33191.
83. Xu Q., et al. Roles of N-acetylglucosaminyltransferase III in epithelial-to-mesenchymal transition induced by transforming growth factor β1 (TGF-β1) in epithelial cell lines. J. Biol. Chem. 2012, 287:16563-16574.
84. Tian H., et al. The implication of N-acetylglucosaminyltransferase V expression in gastric cancer. Pathobiology 2008, 75:288-294.
85. Granovsky M., et al. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med. 2000, 6:306-312.
86. Taniguchi N., Korekane H. Branched N-glycans and their implications for cell adhesion, signaling and clinical applications for cancer biomarkers and in therapeutics. BMB Rep. 2011, 44:772-781.
87. Terao M., et al. Enhanced epithelial-mesenchymal transition-like phenotype in N-acetylglucosaminyltransferase V transgenic mouse skin promotes wound healing. J. Biol. Chem. 2011, 286:28303-28311.
88. Guo H.B., et al. N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J. Biol. Chem. 2003, 278:52412-52424.
89. Zhao Y., et al. N-acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. J. Biol. Chem. 2006, 281:32122-32130.
90. Ihara S., et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching. J. Biol. Chem. 2002, 277:16960-16967.
91. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
92. Liddington R.C., Ginsberg M.H. Integrin activation takes shape. J. Cell Biol. 2002, 158:833-839.
93. Bellis S.L. Variant glycosylation: an underappreciated regulatory mechanism for β1 integrins. Biochim. Biophys. Acta 2004, 1663:52-60.
94. Gu J., Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj. J. 2004, 21:9-15.
95. Chammas R., et al. Asn-linked oligosaccharide-dependent interaction between laminin and gp120/140. An α6/β1 integrin. J. Biol. Chem. 1991, 266:3349-3355.
96. Isaji T., et al. N-glycosylation of the I-like domain of β1 integrin is essential for β1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for α5β1. J. Biol. Chem. 2009, 284:12207-12216.
97. Isaji T., et al. N-glycosylation of the β-propeller domain of the integrin α5 subunit is essential for α5β1 heterodimerization, expression on the cell surface, and its biological function. J. Biol. Chem. 2006, 281:33258-33267.
98. Asada M., et al. Increased expression of highly branched N-glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. Cancer Res. 1997, 57:1073-1080.
99. Pochec E., et al. Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochim. Biophys. Acta 2003, 1643:113-123.
100. Gu J., et al. Potential roles of N-glycosylation in cell adhesion. Glycoconj. J. 2012, 29:599-607.
101. Gu J., Taniguchi N. Potential of N-glycan in cell adhesion and migration as either a positive or negative regulator. Cell Adh. Migr. 2008, 2:243-245.
102. Isaji T., et al. Introduction of bisecting GlcNAc into integrin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J. Biol. Chem. 2004, 279:19747-19754.
103. Sato Y., et al. An N-glycosylation site on the beta-propeller domain of the integrin α5 subunit plays key roles in both its function and site-specific modification by β1,4-N-acetylglucosaminyltransferase III. J. Biol. Chem. 2009, 284:11873-11881.
104. Amado M., et al. Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology 1998, 114:462-470.
105. Gomes C., et al. Expression of ST3GAL4 leads to SLex expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS ONE 2013, 8:e66737.
106. David L., et al. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl. 1992, 27:162-172.
107. Nakagoe T., et al. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res. 2002, 22:451-458.
108. Werther J.L., et al. Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int. J. Cancer 1996, 69:193-199.
109. Marcos N.T., et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci. (Elite Ed.) 2011, 3:1443-1455.
110. Marcos N.T., et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004, 64:7050-7057.
111. Pinho S., et al. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 2007, 249:157-170.
112. Reis C.A., et al. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 2010, 63:322-329.
113. Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005, 4:477-488.
114. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
115. Packer N.H., et al. Frontiers in glycomics: bioinformatics and biomarkers in disease. An NIH white paper prepared from discussions by the focus groups at a workshop on the NIH campus, Bethesda MD (September 11-13, 2006). Proteomics 2008, 8:8-20.
116. Taniguchi N. Human disease glycomics/proteome initiative (HGPI). Mol. Cell. Proteomics 2008, 7:626-627.
117. Shukla H.D., et al. Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective. Proteomics 2012, 12:3085-3104.
118. Li D., et al. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 2001, 313:15-19.
119. Korekane H., et al. Development of an antibody-lectin enzyme immunoassay for fucosylated α-fetoprotein. Biochim. Biophys. Acta 2012, 1820:1405-1411.
120. Miyoshi E., et al. Identification of fucosylated haptoglobin as a novel tumor marker for pancreatic cancer and its possible application for a clinical diagnostic test. Methods Enzymol. 2010, 478:153-164.
121. Park S.Y., et al. α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int. J. Cancer 2012, 130:2366-2376.
122. Malagolini N., et al. Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon. Glycobiology 2007, 17:688-697.
123. Beheshti Zavareh R., et al. Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res. 2008, 68:6688-6697.
124. Contessa J.N., et al. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 2010, 16:3205-3214.
125. Dennis J.W. Effects of swainsonine and polyinosinic:polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res. 1986, 46:5131-5136.
126. Sun J.Y., et al. Inhibition of the growth of human gastric carcinoma in vivo and in vitro by swainsonine. Phytomedicine 2007, 14:353-359.
127. Goss P.E., et al. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin. Cancer Res. 1997, 3:1077-1086.
128. Shaheen P.E., et al. Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma. Invest. New Drugs 2005, 23:577-581.
129. Buskas T., et al. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem. Commun. (Camb.) 2009, 36:5335-5349.
130. Li M., et al. Glycan changes: cancer metastasis and anti-cancer vaccines. J. Biosci. 2010, 35:665-673.
131. Beatson R.E., et al. MUC1 immunotherapy. Immunotherapy 2010, 2:305-327.
132. Lavrsen K., et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj. J. 2013, 30:227-236.
133. Julien S., et al. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100:1746-1754.
134. Taniguchi N., et al. The second golden age of glycomics: from functional glycomics to clinical applications. J. Proteome Res. 2009, 8:425-426.
135. Lebrilla C.B., An H.J. The prospects of glycan biomarkers for the diagnosis of diseases. Mol. Biosyst. 2009, 5:17-20.
136. Oliveira C., et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum. Mol. Genet. 2009, 18:1545-1555.
137. Carvalho J., et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J. Pathol. 2012, 228:31-44.
138. Machado J.C., et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001, 20:1525-1528.
139. Barber M., et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J. Pathol. 2008, 216:295-306.
140. Oliveira C., et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009, 136:2137-2148.
141. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
142. Gregory P.A., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.